Report cover image

Global Medications for Smoking Cessation Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 194 Pages
SKU # APRC20360459

Description

Summary

According to APO Research, the global Medications for Smoking Cessation market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Medications for Smoking Cessation is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Medications for Smoking Cessation is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Medications for Smoking Cessation market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Medications for Smoking Cessation is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Medications for Smoking Cessation market include Johnson & Johnson, NovartisNjoy Inc, Pfizer, GlaxoSmithKline, Perrigo and Reynolds American Inc., Nicotek, Fontem Ventures, Dr Reddy's Laboratories and Cipla, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Medications for Smoking Cessation, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Medications for Smoking Cessation, also provides the value of main regions and countries. Of the upcoming market potential for Medications for Smoking Cessation, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Medications for Smoking Cessation revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Medications for Smoking Cessation market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Medications for Smoking Cessation company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Medications for Smoking Cessation Segment by Company

Johnson & Johnson
NovartisNjoy Inc
Pfizer
GlaxoSmithKline
Perrigo and Reynolds American Inc.
Nicotek
Fontem Ventures
Dr Reddy's Laboratories
Cipla
Medications for Smoking Cessation Segment by Type

Non Nicotine Drugs
Nicotine Replacement Therapy (NRT)
Medications for Smoking Cessation Segment by Application

Hospital Pharmacies
Online Pharmacies
Retailer Pharmacies
Medications for Smoking Cessation Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Medications for Smoking Cessation status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Medications for Smoking Cessation key companies, revenue, market share, and recent developments.
3. To split the Medications for Smoking Cessation breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Medications for Smoking Cessation market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Medications for Smoking Cessation significant trends, drivers, influence factors in global and regions.
6. To analyze Medications for Smoking Cessation competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medications for Smoking Cessation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medications for Smoking Cessation and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medications for Smoking Cessation.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Medications for Smoking Cessation industry.
Chapter 3: Detailed analysis of Medications for Smoking Cessation company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Medications for Smoking Cessation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Medications for Smoking Cessation in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Medications for Smoking Cessation Market Size, 2020 VS 2024 VS 2031
1.3 Global Medications for Smoking Cessation Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Medications for Smoking Cessation Market Dynamics
2.1 Medications for Smoking Cessation Industry Trends
2.2 Medications for Smoking Cessation Industry Drivers
2.3 Medications for Smoking Cessation Industry Opportunities and Challenges
2.4 Medications for Smoking Cessation Industry Restraints
3 Medications for Smoking Cessation Market by Company
3.1 Global Medications for Smoking Cessation Company Revenue Ranking in 2024
3.2 Global Medications for Smoking Cessation Revenue by Company (2020-2025)
3.3 Global Medications for Smoking Cessation Company Ranking (2023-2025)
3.4 Global Medications for Smoking Cessation Company Manufacturing Base and Headquarters
3.5 Global Medications for Smoking Cessation Company Product Type and Application
3.6 Global Medications for Smoking Cessation Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Medications for Smoking Cessation Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Medications for Smoking Cessation Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Medications for Smoking Cessation Market by Type
4.1 Medications for Smoking Cessation Type Introduction
4.1.1 Non Nicotine Drugs
4.1.2 Nicotine Replacement Therapy (NRT)
4.2 Global Medications for Smoking Cessation Sales Value by Type
4.2.1 Global Medications for Smoking Cessation Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Medications for Smoking Cessation Sales Value by Type (2020-2031)
4.2.3 Global Medications for Smoking Cessation Sales Value Share by Type (2020-2031)
5 Medications for Smoking Cessation Market by Application
5.1 Medications for Smoking Cessation Application Introduction
5.1.1 Hospital Pharmacies
5.1.2 Online Pharmacies
5.1.3 Retailer Pharmacies
5.2 Global Medications for Smoking Cessation Sales Value by Application
5.2.1 Global Medications for Smoking Cessation Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Medications for Smoking Cessation Sales Value by Application (2020-2031)
5.2.3 Global Medications for Smoking Cessation Sales Value Share by Application (2020-2031)
6 Medications for Smoking Cessation Regional Value Analysis
6.1 Global Medications for Smoking Cessation Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Medications for Smoking Cessation Sales Value by Region (2020-2031)
6.2.1 Global Medications for Smoking Cessation Sales Value by Region: 2020-2025
6.2.2 Global Medications for Smoking Cessation Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Medications for Smoking Cessation Sales Value (2020-2031)
6.3.2 North America Medications for Smoking Cessation Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Medications for Smoking Cessation Sales Value (2020-2031)
6.4.2 Europe Medications for Smoking Cessation Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Medications for Smoking Cessation Sales Value (2020-2031)
6.5.2 Asia-Pacific Medications for Smoking Cessation Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Medications for Smoking Cessation Sales Value (2020-2031)
6.6.2 South America Medications for Smoking Cessation Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Medications for Smoking Cessation Sales Value (2020-2031)
6.7.2 Middle East & Africa Medications for Smoking Cessation Sales Value Share by Country, 2024 VS 2031
7 Medications for Smoking Cessation Country-level Value Analysis
7.1 Global Medications for Smoking Cessation Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Medications for Smoking Cessation Sales Value by Country (2020-2031)
7.2.1 Global Medications for Smoking Cessation Sales Value by Country (2020-2025)
7.2.2 Global Medications for Smoking Cessation Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.3.2 USA Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.4.2 Canada Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.6.2 Germany Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.7.2 France Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.7.3 France Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.9.2 Italy Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.10.2 Spain Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.11.2 Russia Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.14.2 China Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.14.3 China Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.15.2 Japan Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.17.2 India Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.17.3 India Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.18.2 Australia Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.22.2 Chile Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.24.2 Peru Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.26.2 Israel Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.27.2 UAE Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.29.2 Iran Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Medications for Smoking Cessation Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Medications for Smoking Cessation Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Medications for Smoking Cessation Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Johnson & Johnson
8.1.1 Johnson & Johnson Comapny Information
8.1.2 Johnson & Johnson Business Overview
8.1.3 Johnson & Johnson Medications for Smoking Cessation Revenue and Gross Margin (2020-2025)
8.1.4 Johnson & Johnson Medications for Smoking Cessation Product Portfolio
8.1.5 Johnson & Johnson Recent Developments
8.2 NovartisNjoy Inc
8.2.1 NovartisNjoy Inc Comapny Information
8.2.2 NovartisNjoy Inc Business Overview
8.2.3 NovartisNjoy Inc Medications for Smoking Cessation Revenue and Gross Margin (2020-2025)
8.2.4 NovartisNjoy Inc Medications for Smoking Cessation Product Portfolio
8.2.5 NovartisNjoy Inc Recent Developments
8.3 Pfizer
8.3.1 Pfizer Comapny Information
8.3.2 Pfizer Business Overview
8.3.3 Pfizer Medications for Smoking Cessation Revenue and Gross Margin (2020-2025)
8.3.4 Pfizer Medications for Smoking Cessation Product Portfolio
8.3.5 Pfizer Recent Developments
8.4 GlaxoSmithKline
8.4.1 GlaxoSmithKline Comapny Information
8.4.2 GlaxoSmithKline Business Overview
8.4.3 GlaxoSmithKline Medications for Smoking Cessation Revenue and Gross Margin (2020-2025)
8.4.4 GlaxoSmithKline Medications for Smoking Cessation Product Portfolio
8.4.5 GlaxoSmithKline Recent Developments
8.5 Perrigo and Reynolds American Inc.
8.5.1 Perrigo and Reynolds American Inc. Comapny Information
8.5.2 Perrigo and Reynolds American Inc. Business Overview
8.5.3 Perrigo and Reynolds American Inc. Medications for Smoking Cessation Revenue and Gross Margin (2020-2025)
8.5.4 Perrigo and Reynolds American Inc. Medications for Smoking Cessation Product Portfolio
8.5.5 Perrigo and Reynolds American Inc. Recent Developments
8.6 Nicotek
8.6.1 Nicotek Comapny Information
8.6.2 Nicotek Business Overview
8.6.3 Nicotek Medications for Smoking Cessation Revenue and Gross Margin (2020-2025)
8.6.4 Nicotek Medications for Smoking Cessation Product Portfolio
8.6.5 Nicotek Recent Developments
8.7 Fontem Ventures
8.7.1 Fontem Ventures Comapny Information
8.7.2 Fontem Ventures Business Overview
8.7.3 Fontem Ventures Medications for Smoking Cessation Revenue and Gross Margin (2020-2025)
8.7.4 Fontem Ventures Medications for Smoking Cessation Product Portfolio
8.7.5 Fontem Ventures Recent Developments
8.8 Dr Reddy's Laboratories
8.8.1 Dr Reddy's Laboratories Comapny Information
8.8.2 Dr Reddy's Laboratories Business Overview
8.8.3 Dr Reddy's Laboratories Medications for Smoking Cessation Revenue and Gross Margin (2020-2025)
8.8.4 Dr Reddy's Laboratories Medications for Smoking Cessation Product Portfolio
8.8.5 Dr Reddy's Laboratories Recent Developments
8.9 Cipla
8.9.1 Cipla Comapny Information
8.9.2 Cipla Business Overview
8.9.3 Cipla Medications for Smoking Cessation Revenue and Gross Margin (2020-2025)
8.9.4 Cipla Medications for Smoking Cessation Product Portfolio
8.9.5 Cipla Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.